Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Statins for Prevention of CVD in the Elderly

BMJ; ePub 2018 Sep 5; Ramos, Comas-Cuff, et al

Statin treatment was not associated with a reduction in atherosclerotic cardiovascular disease (CVD) or in all-cause mortality in patients aged >74 years without type 2 diabetes (T2D), a recent study found. The retrospective cohort included 46,864 people aged ≥75 years without clinically recognized atherosclerotic CVD. Participants were stratified by presence of T2D and as statin non-users or new users. Researchers found:

  • Statins were not associated with a reduction in atherosclerotic CVD or all-cause mortality in primary prevention in participants without diabetes aged >74 years independently of age subgroup.
  • In the presence of diabetes, however, statin use was statistically significantly associated with reductions in the incidence of atherosclerotic CVD and in all-cause mortality.
  • This effect decreased after age 85 years and disappeared in nonagenarians.


Ramos R, Comas-Cuff M, Martí-Lluch R, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: Retrospective cohort study. [Published online ahead of print September 5, 2018]. BMJ. doi:10.1136/bmj.k3359.